Saxenda® is a once-daily glucagon-like peptide-1 (GLP-1) analogue indicated as an adjunct to a reduced calorie diet and increased physical activity for weight management in adult patients with an initial body mass index of:1
- ≥30 kg/m² (obese)
- ≥27 kg/m² to <30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (prediabetes or type 2 diabetes), hypertension, dyslipidaemia, or obstructive sleep apnoea.
Saxenda® should be discontinued after 12 weeks on the 3.0 mg/day dose if patients have not lost at least 5% of their initial body weight.1
The exact mechanism of action is not entirely clear. GLP-1 is a physiological regulator of appetite and food intake. Similar to native GLP-1, Saxenda® works in the braina to decrease appetite and thereby reduce food intake.1
Saxenda® Mechanism of Action (MoA)
aShown in animal models.
Watch how Saxenda® works in the body
- Saxenda® Summary of Product Characteristics.
- Orskov C, Wettergren A, Holst JJ. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol. 1996;31(7):665-670.
- Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998;101(3):515-520.